@entity39707 increased @entity79 and @entity79 to a significantly greater extent than @entity441 . The hot flush incidence was lower with @entity39707 than @entity441 . INTRODUCTION: To assess the effect of @entity39707 versus @entity441 on change in lumbar spine (LS) @entity79 ( @entity79 ) in postmenopausal @entity1 with @entity170 . METHODS: In this 12-month study (NEXT trial), @entity1 were randomly assigned to @entity39707 20 mg/day (N = 158) or @entity441 60 mg/day (N = 162). All received daily @entity460 and @entity560 . Change in LS @entity79 was assessed by DXA. Secondary objectives included assessment of femoral neck (FN) and total hip @entity79 , serum bone turnover markers, and safety. RESULTS: Treatment groups were similar at baseline (mean age 63 years, mean LS @entity79 T-score -2.9). At 12 months, the increase in LS @entity79 with @entity39707 was greater than with @entity441 (+2.75% vs. +1.66%), as was @entity79 (P < 0.05). For LS and FN, this effect was also evident at 6 months. @entity39707 reduced bone turnover to a greater extent than @entity441 at 3, 6, and 12 months (P < 0.05). The proportion of @entity1 reporting >=  1 adverse event did not differ between treatment groups, nor did @entity3556 . No cases of @entity1869 , or @entity5 were reported. @entity11266 and @entity3617 were reported more frequently with @entity39707 versus @entity441 (10.1% vs. 2.5%, and 5.1% vs. 0%, respectively) and new/worsening hot flushes were reported less frequently with @entity39707 (7.0% vs. 16.7%) (P < 0.05). CONCLUSIONS: @entity39707 increased @entity79 and suppressed bone turnover to a greater extent than @entity441 and resulted in a lower incidence of new/worsening hot flushes. Based on subsequent findings from a fracture outcome study, this difference did not translate into improved fracture efficacy.

@entity39707 versus XXXX : effect on bone and safety parameters in postmenopausal @entity1 with @entity170 .

@entity1 :: ('9606', 'Species') :: ['participants', 'women'] @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis'] @entity11266 :: ('MESH:D009304', 'Disease') :: ['Nasopharyngitis'] @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD', 'FN and total hip BMD', 'decreased bone turnover'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity39707 :: ('MESH:C115121', 'Chemical') :: ['arzoxifene', 'Arzoxifene'] @entity1869 :: ('MESH:D004714', 'Disease') :: ['endometrial polyps, hyperplasia'] @entity441 :: ('MESH:D020849', 'Chemical') :: ['raloxifene'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity441 :: (MESH:D020849,Chemical) :: ['raloxifene']
